Brought to you by 
Navidea receives option on Alseres’ Parkinson’s imaging agent; terminated
04 Apr 2016
Executive Summary
Over the next six months, radiopharmaceuticals company Navidea Biopharmaceuticals Inc. has an exclusive option to license the Phase III molecular imaging agent Altropane (123I-E-IAFCT injection) from Alseres Pharmaceuticals Inc., which has been focusing on the development of this Parkinson’s disease program (the company also has nerve cell regeneration candidates, but is no longer investing in them).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Navidea receives option on Alseres’ Parkinson’s imaging agent; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice